Skip to content
DataLookout
Menu

NCT07487844

Pulsed Electric Field Ablation for Metastatic Breast Cancer

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Primary and study completion pushed from Aug 1, 2028 to Dec 31, 2028
    • Site contact updated
  2. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 20 words
    • Start date changed from estimate of Aug 15, 2026 to Jun 29, 2026
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site details revised
  3. Notable Start date: May 15, 2026 to Aug 15, 2026
    • Primary and study completion pushed from Jul 1, 2028 to Aug 1, 2028
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of participants with treatment-emergent adverse events
Timeframe: Up to 4 weeks

Secondary (3)

Mean change of score on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Breast Cancer Module (EORTC QLQ BR-23)
Mean change of score on EuroQol five-dimensional Questionnaire (EQ-5D)
Mean technical success rate of Pulsed Electric Field (PEF) ablation

Arms and interventions

Image-Guided Pulsed Electric Field (PEF) AblationExperimental

Participants undergo a single treatment of PEF ablation delivered to up to 3 soft tissue metastatic breast cancer lesion(s). Ablation parameters, immediate adverse events, and post-ablation imaging will be collected during the ablation treatment.

Devices: Pulsed Electric Field (PEF) System

Behavioral: Questionnaires

Procedures: Tumor Ablation

Sites

1 site in 1 country

  • University of California San FranciscoSan Francisco, California, United States